Covalent Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Covalent Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-800	Closed	-$450K	–	17
2025 Q3	$450K	Buy	+800	New	+$452K	1.69%	16

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Covalent Partners's REGN Position: Q4 2025 in Review

Covalent Partners sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 800 shares — an estimated $450K sold.

Covalent Partners first reported a position in REGN in Q3 2025 and held it in 1 quarter. The position peaked at $450K in Q3 2025. 1,388 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

Covalent Partners reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Covalent Partners sold 800 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $450K.
Covalent Partners first reported a position in Regeneron Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Covalent Partners's Regeneron Pharmaceuticals position peaked at $450K in Q3 2025.
1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Covalent Partners's 13F filing for Q4 2025, filed 17 Feb 2026.